Follow-on Protocol of Pitavastatin Versus Simvastatin in Patients With Hypercholesterolemia or Dyslipidemia and Coronary Heart Disease Risk Factors
Double-blind follow-on Study of Pitavastatin (4mg) Versus Simvastatin (40mg and 80mg) With a Single-blind Extension of Treatment in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia and 2 or More Risk Factors for Coronary Heart Disease
1 other identifier
interventional
178
4 countries
28
Brief Summary
This is a sixteen-week follow-on and 28 week single-blind extension study for patients who participated in study NK-104-304.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3
Started Jun 2006
Shorter than P25 for phase_3
28 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2006
CompletedFirst Submitted
Initial submission to the registry
June 22, 2006
CompletedFirst Posted
Study publicly available on registry
June 26, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2007
CompletedResults Posted
Study results publicly available
January 18, 2010
CompletedFebruary 2, 2010
January 1, 2010
1.2 years
June 22, 2006
September 1, 2009
January 25, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Number of Patients Attaining NCEP LDL-C Target at Week 16
Number of patients attaining the National Cholesterol Education Program (NCEP) LDL-C target at Week 16. According to NCEP criteria the target LDL-C is 100 mg/dL.
16 weeks
Number of Patients Attaining NCEP LDL-C Target at Week 44
Number of patients attaining National Cholesterol Education Program (NCEP) LDL-C target at Week 44. According to NCEP criteria the target LDL-C is 100 mg/dL.
44 Weeks
Secondary Outcomes (1)
Percent Change From Baseline in LDL-C
Baseline to 44 weeks
Study Arms (2)
Pitavastatin 4 mg
EXPERIMENTALPitavastatin 4 mg once daily
Simvastatin 40mg/80mg
ACTIVE COMPARATORSimvastatin 40 mg or 80 mg once daily
Interventions
Eligibility Criteria
You may qualify if:
- Completed NK-104-304 (NCT 00309738)
- Hypercholesterolemia or combined dyslipidemia
- or more risk factors for coronary heart disease (CHD)
You may not qualify if:
- Withdrawn or terminated from NK-104-304 (00309738)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (28)
Y Forskning, Bispebjerg Hospital
Copenhagen Nv, Denmark
Frederiks Hospital, Kardiologisk
Frederiksberg, Denmark
Kolesterollaboratoriet
Hellerup, Denmark
CCBR A/S
Vejle, Denmark
Middellaan 5
Breda, Netherlands
Bomanshof 8
Eindhoven, Netherlands
Damsterdiep 9
Groningen, Netherlands
Doezastraat 1
Leiden, Netherlands
Kamerlingh Onnesstraat 16-18
Nijmegen, Netherlands
Mathenesserlaan 247
Rotterdam, Netherlands
Reigerstraat 30
Velp, Netherlands
Parkdreef 142
Zoetermeer, Netherlands
Hospital Clinico S. Juan de Alicante
San Juan, Alicante, Spain
Hospital Universitario Reina Sofia
Córdoba, Spain
Hospital Ramon y Cajal
Madrid, 28000, Spain
Fundacion Jimenez Diaz
Madrid, Spain
Hospital Clinico San Carlos
Madrid, Spain
Hospital Clinico Universitario de Santiago
Santiago de Compostela, Spain
Angelholms Sjukhus, Medicinkliniken
Angelhom, Sweden
Sahlgrenska University Hospital, Intermedicin
Gothenburg, Sweden
Hjartmottagningen
Helsingborg, Sweden
Lakarcentrum Nyponet
Karineholm, Sweden
Medicinkliniken
Ludvika, Sweden
Huslakaren i Sandviken
Sandviken, Sweden
Narsjukhuset Sandviken, Kardiologlab, Medicin
Sandviken, Sweden
Hjart & Karlcenter
Södertälje, Sweden
Karolinska Universitetssjukhuset
Stockholm, Sweden
Hjarthuset AB
Varberg, Sweden
Related Publications (1)
Eriksson M, Budinski D, Hounslow N. Long-term efficacy of pitavastatin versus simvastatin. Adv Ther. 2011 Sep;28(9):799-810. doi: 10.1007/s12325-011-0057-6. Epub 2011 Aug 25.
PMID: 21874537DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Bill Arana
- Organization
- Kowa Research Institute
Study Officials
- STUDY DIRECTOR
Dragos Budinski, MD
Kowa Research Europe
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- GT60
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
June 22, 2006
First Posted
June 26, 2006
Study Start
June 1, 2006
Primary Completion
August 1, 2007
Study Completion
August 1, 2007
Last Updated
February 2, 2010
Results First Posted
January 18, 2010
Record last verified: 2010-01